Inhibikase Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDInhibikase Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 65), indicating performance broadly in line with the market. Earnings contraction of 13% provides fundamental context to the price action. Investors should exercise caution due to high volatility (70% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.80 | +10.00% | ABOVE |
| 50 SMA | $1.81 | +9.32% | ABOVE |
| 100 SMA | $1.81 | +9.41% | ABOVE |
| 150 SMA | $1.76 | +12.44% | ABOVE |
| 200 SMA | $1.72 | +15.43% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is IKT in an uptrend right now?
IKT has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, IKT is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is IKT overbought or oversold?
IKT's RSI (14) is 66. The stock is in neutral territory, neither overbought nor oversold.
Is IKT outperforming the market?
IKT has a Relative Strength (RS) Rating of 65 out of 99. IKT is performing about average compared to the market.
Where is IKT in its 52-week range?
IKT is trading at $1.98, which is 88% of its 52-week high ($2.26) and 70% above its 52-week low ($1.33).
How volatile is IKT?
IKT has a Beta of 1.75 and 52-week volatility of 70%. It's more volatile than the S&P 500 - expect bigger swings.